chansin
2021-07-12

"The proposed merger with Advaxis is a unique opportunity for Biosight to build a leading public company in oncology, with a diversified clinical pipeline in both hematological malignancies and solid tumors. The combined company will have the demonstrated expertise and strong balance sheet to advance its lead programs towards multiple anticipated milestones over the next 12 to 18 months."

Dr. Ruth Ben Yakar, CEO of Biosigh

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

精彩评论

  • 36cb5dc0
    2021-07-15
    36cb5dc0
    感觉象只“原油宝”?
  • 兮惜168
    2021-07-12
    兮惜168
    会起飞吗?
发表看法
7